At Velakor Biotherapeutics, we are developing CAM-6019, a revolutionary therapy that taps into the body’s innate ability to repair cardiac tissue, similar to the regenerative capabilities seen in infancy.
By mimicking the young, pro-regenerative cardiac extra cellular matrix (ECM), our innovative approach has demonstrated significant potential in protecting and regenerating the heart in multiple animal models of heart attack or heart failure.
More than 6 million Americans suffer heart failure today, and cardiovascular diseases kills more people than all forms of cancer combined. Current Standard of Care treatments offer only modest symptom relief and reduced hospitalizations, failing to protect or regenerate heart tissue. As a result, their impact on the progression of heart disease remains limited, highlighting the urgent need for innovative solutions.
Americans have heart failure today
Americans will have heart failure by 2030
Americans suffer severe heart attacks annually
CAM-6019 is our groundbreaking therapy designed to address the pressing challenges of ischemic heart disease. A derivative of the extracellular matrix (ECM) proteoglycan Agrin, CAM-6019 offers a novel approach to cardiac care.
This innovative biologic targets the heart's innate regenerative capabilities aiming to promote the healing and recovery of the injured cardiac tissue. By focusing on the underlying mechanisms of ischemic heart disease, CAM-6019 aspires to enhance patient outcomes and improve the quality of life for those affected by this debilitating condition.
At Velakor Biotherapeutics, we are developing CAM-6019, a revolutionary therapy that taps into the body’s innate ability to repair cardiac tissue, similar to the regenerative capabilities seen in infancy. By focusing on mimicking the young, regenerative extracellular matrix (ECM), our innovative approach has demonstrated significant potential to protect and regenerate heart tissue in animal models of heart attack or heart failure.
.svg)
.svg)